Webber Christina M, Caldwell Brittany, Bocell Fraser D, Saha Anindita, Tarver Michelle E
Center for Devices and Radiological Health, U.S. Food and Drug Administration, Silver Spring, MD, USA.
J Patient Rep Outcomes. 2022 May 24;6(1):53. doi: 10.1186/s41687-022-00463-w.
The insights gleaned from patient-reported outcomes (PROs) have implications across the healthcare ecosystem, from clinical investigations to evaluate the safety and effectiveness of medical devices to clinical care and reimbursement decisions. The U.S. Food and Drug Administration's (FDA) Center for Devices and Radiological Health (CDRH) hosted a public meeting in September 2020 discussing how PROs can be used in medical device evaluation throughout the total product life cycle, as well as methods for developing and modifying PRO instruments to ensure they are fit-for-purpose. This commentary presents key points of discussion from the meeting, providing insight into the increased interest in PRO data to support medical product development while also exploring future opportunities of incorporating PRO data throughout healthcare.
Thoughtful use of fit-for-purpose PRO instruments to integrate the patient's voice into clinical care paradigms, medical device development, regulatory decisions, and reimbursement and coverage decisions were emphasized throughout the meeting. Existing PRO instruments may be used if the context of use is appropriate. Modifications to an existing PRO instrument may also be explored to ensure the instrument is fit-for-purpose in a new context of use. Development of a novel PRO instrument may be necessary to capture attributes in a new patient population or application. Multi-stakeholder collaborations, of which patients are a key component, create efficiencies in the development and modification of PRO instruments.
Continued multi-stakeholder collaborations bringing together researchers, clinicians, patients, regulators, and payers are critical to further advance the inclusion of the patient voice incorporating PRO instruments throughout the healthcare ecosystem in an efficient manner that is least burdensome to patients.
从患者报告结局(PROs)中获得的见解对整个医疗保健生态系统都有影响,从评估医疗设备安全性和有效性的临床研究到临床护理以及报销决策。美国食品药品监督管理局(FDA)的设备与放射健康中心(CDRH)于2020年9月举办了一次公开会议,讨论如何在整个产品生命周期中将PROs用于医疗设备评估,以及开发和修改PRO工具以确保其适用的方法。本评论介绍了会议的主要讨论要点,深入探讨了对支持医疗产品开发的PRO数据的兴趣增加,同时也探索了在整个医疗保健领域纳入PRO数据的未来机会。
会议始终强调,要审慎使用适用的PRO工具,将患者的声音融入临床护理模式、医疗设备开发、监管决策以及报销和覆盖范围决策中。如果使用背景合适,可以使用现有的PRO工具。也可以探索对现有PRO工具进行修改,以确保该工具在新的使用背景下适用。可能需要开发新的PRO工具来获取新患者群体或应用中的属性。多利益相关方合作(患者是关键组成部分)能提高PRO工具开发和修改的效率。
研究人员、临床医生、患者、监管机构和支付方持续开展多利益相关方合作,对于以对患者负担最小的高效方式,进一步推动将患者声音纳入整个医疗保健生态系统中的PRO工具至关重要。